治疗乳腺癌小分子药物研究进展

Progress of research in small molecule drugs for breast cancer

乳腺癌是我国常见的一种恶性肿瘤,发病率日渐增加并年轻化,严重威胁着女性身体健康。随着近些年来医学包括药物化学的发展,多种针对乳腺癌靶标的小分子化合药物已在临床上被广泛使用,取得了相当的疗效。本文就乳腺癌的相关靶标如雌激素受体、细胞色素、核受体家族进行简要介绍并且就一些常用的小分子药物如雷诺昔芬、托瑞米芬、他莫昔芬、阿那曲唑、依西美坦、来曲唑、紫杉醇、多西紫杉醇等药物的临床治疗、不良反应及不同药物疗效对比的研究进展进行综述。

Breast cancer is a common malignant tumor in China. Its prevalence is increasing and the patients are getting younger,and thus it is a great threat to the health of women. These years,with the development of medicine（ including pharmaceutical chemistry）,many kinds of small molecule drugs targeting for breast cancer have been applied in clinic and achieved considerable curative effects.In this paper,the author overviews the recent research progress in some targets of breast cancer（ estrogen receptor,cytochrome,nuclear receptor subfamily） and some relative small molecule drugs（ Raloxifene,Toremifene,Tamoxifen,Anastrozole,Exemestane,Letrozole,Paclitaxel,Docetaxel） in their clinical treatments,adverse reactions and contrasts of their curative effects.